ArticleJournal, genetic engineering & biotechnology2026
ResSGA-Net: A deep learning approach for enhanced brain tumor detection and accurate classification in healthcare imaging systems.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Brain Tumor Segmentation and Grading on MRI Using Deep Learning: A Systematic Literature Review and Benchmark-Driven Comparative Analysis.Diagnostics (Basel, Switzerland) · 2026Review
- Hyperparameter Optimization of Convolutional Neural Networks for Robust Tumor Image Classification.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and reliable brain tumor classification from magnetic resonance imaging (MRI) is a critical component of computer-aided diagnosis systems, directly impacting clinical decision-making and patient outcomes. This study presents ResSGA-Net, a hybrid deep learning framework that integrates a ResNet50 backbone with dual attention mechanisms (global and gated) and a Swin Transformer to capture both fine-grained local features and long-range contextual dependencies effectively. A fusion strategy is employed to unify convolutional, attention-refined, and transformer-enhanced representations into a robust feature space for multi-class classification. The proposed model is evaluated on two publicly available benchmark datasets, including a four-class and a three-class brain tumor classification task, using stratified cross-validation. Extensive quantitative analysis demonstrates that ResSGA-Net achieves state-of-the-art performance, with accuracies exceeding 98% on Dataset I and strong generalization on Dataset II (accuracy of 93.18% and macro-averaged AUC of 0.989). Comprehensive statistical significance testing confirms that the observed improvements are highly significant and not attributable to random chance. Ablation studies further validate the individual contributions of attention mechanisms and data augmentation strategies, demonstrating that performance gains arise from tumor-specific feature learning rather than artificial data diversity. Qualitative analyses, including confusion matrices, training dynamics, ROC curves, and confidence-based visualizations, confirm stable convergence, robust generalization, and reliable decision confidence across tumor classes. These results indicate that ResSGA-Net provides an accurate, stable, and clinically meaningful solution for automated brain tumor classification, with strong potential for integration into real-world diagnostic imaging workflows.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.